Tissue stiffness tells a clinical story that B-mode alone cannot. Elastography layers quantitative stiffness data onto standard ultrasound imaging, letting a hepatologist stage liver fibrosis without a biopsy, a breast radiologist characterize a suspicious lesion before deciding on biopsy, or a thyroid specialist assess nodule characteristics that inform fine-needle aspiration decisions. That additional diagnostic layer sits on top of the standard ultrasound platform, which means the machine earning its keep on routine studies also earns on the elastography protocols layered into the workflow.
Financing an elastography-capable system is a somewhat different conversation than financing a basic imaging platform. The systems that support clinically meaningful elastography (shear-wave elastography in particular, which provides quantitative stiffness measurements in kilopascals or meters per second rather than qualitative strain mapping) are mid- to premium-tier instruments. They cost more, but the return per study is also higher because elastography-coded CPT additions carry incremental reimbursement above the base ultrasound study.